A Single Arm Multicentre Phase II Study of Panitumumab in Combination With Irinotecan/5-fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer.

Trial Profile

A Single Arm Multicentre Phase II Study of Panitumumab in Combination With Irinotecan/5-fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Oct 2016

At a glance

  • Drugs Panitumumab (Primary) ; Fluorouracil; Folinic acid; Irinotecan
  • Indications Colorectal cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 20 Oct 2016 Results of retrospective analysis assessing impact of tumour RAS/BRAF status in a first-line study of panitumumab in combination with FOLFIRI published in the British Journal of Cancer.
    • 02 Jun 2015 Results of analysis of relationship between AREG expression and treatment outcome presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 27 Feb 2015 Based on results of this study, the CHMP of the EMA adopted a positive opinion to extend the marketing authorisation for Vectibix to include combination with FOLFIRI as first-line treatment for wild-type RAS mCRC, according to an Amgen media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top